Growth Metrics

Alx Oncology Holdings (ALXO) Cash from Financing Activities (2019 - 2026)

Alx Oncology Holdings recorded quarterly Cash from Financing Activities of $139.6 million in Q1 2026, up 20489.23% quarter-over-quarter from $678000.0 in Q4 2025, and up 214661.54% year-over-year from N/an in Q1 2025.

Alx Oncology Holdings' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $139.6 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 214661.54% year-over-year to $139.6 million; the TTM figure through Mar 2026 stood at $139.9 million (up 403.28% YoY), while the FY2025 annual figure was $362000.0, down 98.83% from the prior year.
  • Cash from Financing Activities came in at $139.6 million for Q1 2026 at Alx Oncology Holdings, up from $678000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $139.6 million in Q1 2026 to a low of -$222000.0 in Q2 2025.
  • A 5-year average of $14.1 million and a median of $328000.0 in 2024 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities tumbled 233.75% in 2023 and jumped 214661.54% in 2026, its largest moves.
  • Alx Oncology Holdings' Cash from Financing Activities stood at $9.5 million in 2022, then surged by 523.19% to $59.2 million in 2023, then plunged by 99.45% to $328000.0 in 2024, then surged by 106.71% to $678000.0 in 2025, then soared by 20489.23% to $139.6 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $139.6 million, $678000.0, and -$159000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Alx Oncology Holdings 189.80 Mn 49.48 Mn - 139.60 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 139.60 Mn
Mar 31, 2026 139.60 Mn
Dec 31, 2025 678,000.00
Dec 31, 2025 678,000.00
Sep 30, 2025 -159,000.00
Sep 30, 2025 -159,000.00
Jun 30, 2025 -222,000.00
Jun 30, 2025 -222,000.00
Mar 31, 2025 65,000.00
Mar 31, 2025 65,000.00
Dec 31, 2024 328,000.00
Dec 31, 2024 328,000.00
Sep 30, 2024 251,000.00
Sep 30, 2024 251,000.00
Jun 30, 2024 27.15 Mn
Jun 30, 2024 27.15 Mn
Mar 31, 2024 3.09 Mn
Mar 31, 2024 3.09 Mn
Dec 31, 2023 59.17 Mn
Dec 31, 2023 59.17 Mn
Sep 30, 2023 -111,000.00
Sep 30, 2023 -111,000.00
Jun 30, 2023 343,000.00
Jun 30, 2023 343,000.00
Mar 31, 2023 -107,000.00
Mar 31, 2023 -107,000.00
Dec 31, 2022 9.49 Mn
Dec 31, 2022 9.49 Mn
Sep 30, 2022 -136,000.00
Sep 30, 2022 -136,000.00
Jun 30, 2022 422,000.00
Jun 30, 2022 422,000.00
Mar 31, 2022 80,000.00
Mar 31, 2022 80,000.00
Dec 31, 2021 524,000.00
Dec 31, 2021 524,000.00
Sep 30, 2021 439,000.00
Sep 30, 2021 439,000.00
Jun 30, 2021 731,000.00
Jun 30, 2021 731,000.00
Mar 31, 2021 778,000.00
Mar 31, 2021 778,000.00
Dec 31, 2020 188.36 Mn
Dec 31, 2020 188.36 Mn
Sep 30, 2020 170.30 Mn
Sep 30, 2020 170.30 Mn
Jun 30, 2020 -769,000.00
Jun 30, 2020 -769,000.00
Mar 31, 2020 104.99 Mn
Mar 31, 2020 104.99 Mn
Dec 31, 2019 5.93 Mn
Dec 31, 2019 5.93 Mn